Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III

Journal of Clinical Investigation

Volumn 125, Issue 8, 2015, Pages 3132-3146

  Björkqvist, Jenny ^a,b,c   De Maat, Steven ^d   Lewandrowski, Urs ^e   Di Gennaro, Antonio ^b,c   Oschatz, Chris ^b,c   Schönig, Kai ^f   Nöthen, Markus M ^g   Drouet, Christian ^h   Braley, Hal ⁱ   Nolte, Marc W ^j   Sickmann, Albert ^e   Panousis, Con ⁱ   Maas, Coen ^d   Renné, Thomas ^a,b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h UNIV GRENOBLE ALPES   (France)

ⁱ CSL LIMITED   (Australia)

^j CSL BEHRING GMBH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; ENZYME PRECURSOR; KALLIKREIN; KININ; NEUTRALIZING ANTIBODY;

ANGIONEUROTIC EDEMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; GENE MUTATION; KALLIKREIN KININ SYSTEM; LASER MICROSCOPY; LIVER; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; ADULT; AMINO ACID SUBSTITUTION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; GLYCOSYLATION; HEREDITARY ANGIOEDEMA TYPE III; HUMAN; KNOCKOUT MOUSE; METABOLISM; MISSENSE MUTATION; PATHOLOGY;

ADULT; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, NEUTRALIZING; BLOOD COAGULATION; BRADYKININ; DISEASE MODELS, ANIMAL; FACTOR XII; FEMALE; GLYCOSYLATION; HEREDITARY ANGIOEDEMA TYPE III; HUMANS; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE;

EID: 84939227812     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77139     Document Type: Article

References (72)

1. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
2. Joseph K, Tuscano TB, Kaplan AP. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol. 2008;101(3):279-286.
3. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3(3):311-317.
4. Schapira M, et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med. 1983;308(18):1050-1053.
5. Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor XII. Blood. 2012;120(22):4296-4303.
6. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev. 2005;57(1):27-77.
7. Bjorkqvist J, Sala-Cunill A, Renne T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost. 2013;109(3):368-374.
8. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002;109(8):1057-1063.
9. Zuraw BL, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513-522.
10. Cicardi M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532-541.
11. Cicardi M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363(6):523-531.
12. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356(9225):213-217.
13. Cichon S, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet. 2006;79(6):1098-1104.
14. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006;343(4):1286-1289.
15. Zuraw BL, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012;33(suppl 1):S145-S156.
16. Citarella F, Ravon DM, Pascucci B, Felici A, Fantoni A, Hack CE. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem. 1996;238(1):240-249.
17. McMullen BA, Fujikawa K. Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor). J Biol Chem. 1985;260(9):5328-5341.
18. Björkqvist J, Lecher B, Maas C, Renné T. Zinc-dependent contact system activation induces vascular leakage and hypotension in rodents. Biol Chem. 2013;394(9):1195-1204.
19. Joseph K, Tholanikunnel BG, Bygum A, Ghebrehiwet B, Kaplan AP. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II. J Allergy Clin Immunol. 2013;132(2):470-475.
20. de Maat S, van Dooremalen S, de Groot PG, Maas C. A nanobody-based method for tracking factor XII activation in plasma. Thromb Haemost. 2013;110(3):458-468.
21. Schousboe I. Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor. Eur J Biochem. 2003;270(1):111-118.
22. Siebeck M, et al. Inhibition of plasma kallikrein with aprotinin in porcine endotoxin shock. J Trauma. 1993;34(2):193-198.
23. Larsson M, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 2014;6(222):222ra17.
24. Oschatz C, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity. 2011;34(2):258-268.
25. Kistner A, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1996;93(20):10933-10938.
26. Renne T, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med. 2005;202(2):271-281.
27. Miles AA, Miles EM. Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. J Physiol. 1952;118(2):228-257.
28. Bork K, Kleist R, Hardt J, Witzke G. Kallikreinkinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis. 2009;20(5):325-332.
29. Sala-Cunill A, et al. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol. 2015;135(4):1031-1043.
30. Donaldson VH, Evans RR. A Biochemical Abnormality in Herediatry Angioneurotic Edema: Absence of Serum Inhibitor of C' 1-Esterase. Am J Med. 1963;35:37-44.
31. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet. 2012;379(9814):474-481.
32. Marcos C, Lopez Lera A, Varela S, Linares T, Alvarez-Eire MG, Lopez-Trascasa M. Clinical, biochemical, and genetic characterization of type III hereditary angioedema in 13 Northwest Spanish families. Ann Allergy Asthma Immunol. 2012;109(3):195-200.
33. Martin L, Raison-Peyron N, Nothen MM, Cichon S, Drouet C. Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. J Allergy Clin Immunol. 2007;120(4):975-977.
34. Moreno AS, Arcuri H, Palma M, Arruda LKP. Structural and molecular changes caused by mutations Thr328Lys and Thr328Arg in FXII associated with hereditary angioedema with normal C1 inhibitor. J Allergy Clin Immunol. 2014;133(2):39.
35. Kaplan AP, Gruber B, Harpel PC. Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay. Blood. 1985;66(3):636-641.
36. Bork K, Wulff K, Hardt J, Witzke G, Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol. 2009;124(1):129-134.
37. Pathak M, et al. Coagulation factor XII protease domain crystal structure. J Thromb Haemost. 2015;13(4):580-591.
38. Cugno M, Cicardi M, Coppola R, Agostoni A. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacol. 1996;33(1-3):361-364.
39. Konings J, Cugno M, Suffritti C, Ten Cate H, Cicardi M, Govers-Riemslag JW. Ongoing contact activation in patients with hereditary angioedema. PLoS One. 2013;8(8):e74043.
40. Suffritti C, Zanichelli A, Maggioni L, Bonanni E, Cugno M, Cicardi M. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency. Clin Exp Allergy. 2014;44(12):1503-1514.
41. -/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood. 2015;125(4):710-719.
42. Merkulov S, et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood. 2008;111(3):1274-1281.
43. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost. 2006;95(6):1003-1010.
44. Coffman LG, et al. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol. 2008;294(3):L505-L515.
45. Joseph K, Tholanikunnel BG, Kaplan AP. Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. J Allergy Clin Immunol. 2009;124(1):143-149.
46. Sartor RB, et al. Selective kallikrein-kinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology. 1996;110(5):1467-1481.
47. Uknis AB, DeLa Cadena RA, Janardham R, Sartor RB, Whalley ET, Colman RW. Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat. Inflamm Res. 2001;50(3):149-155.
48. Isordia-Salas I, et al. The mutation Ser511Asn leads to N-glycosylation and increases the cleavage of high molecular weight kininogen in rats genetically susceptible to inflammation. Blood. 2003;102(8):2835-2842.
49. Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol. 2011;141(1):31-35.
50. Bork K, Wulff K, Hardt J, Witzke G. A deletion in the factor 12 gene analysed in two Turkish families with hereditary angioedema with normal C1 inhibitor (HAE type III): a Turkish F12 mutant. Allergy. 2013;68:15.
51. Kiss N, et al. Novel duplication in the F12 gene in a patient with recurrent angioedema. Clin Immunol. 2013;149(1):142-145.
52. Schloesser M, et al. Mutations in the human factor XII gene. Blood. 1997;90(10):3967-3977.
53. Hovinga JK, Schaller J, Stricker H, Wuillemin WA, Furlan M, Lammle B. Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353-->Pro leading to loss of a kallikrein cleavage site. Blood. 1994;84(4):1173-1181.
54. Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost. 2011;37(4):375-381.
55. Bjorkqvist J, Jamsa A, Renne T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost. 2013;110(3):399-407.
56. Hojima Y, Cochrane CG, Wiggins RC, Austen KF, Stevens RL. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood. 1984;63(6):1453-1459.
57. Brunnee T, Reddigari SR, Shibayama Y, Kaplan AP, Silverberg M. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy. 1997;27(6):653-663.
58. Seidel H, et al. Bleeding diathesis in patients with mast cell activation disease. Thromb Haemost. 2011;106(5):987-989.
59. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417-2429.
60. Maas C, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest. 2008;118(9):3208-3218.
61. Kishimoto TK, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358(23):2457-2467.
62. Siebeck M, et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol. 1994;77(6):2675-2680.
63. Muller F, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6):1143-1156.
64. Schmaier AH. The elusive physiologic role of Factor XII. J Clin Invest. 2008;118(9):3006-3009.
65. Matafonov A, et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood. 2014;123(11):1739-1746.
66. Mayforth RD, Quintans J. Designer and catalytic antibodies. N Engl J Med. 1990;323(3):173-178.
67. Chyung Y, et al. A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014;113(4):460-466.
68. Bhattacharjee G, et al. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther. 2013;23(3):175-187.
69. Revenko AS, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood. 2011;118(19):5302-5311.
70. Lewandrowski U, Zahedi RP, Moebius J, Walter U, Sickmann A. Enhanced N-glycosylation site analysis of sialoglycopeptides by strong cation exchange prefractionation applied to platelet plasma membranes. Mol Cell Proteomics. 2007;6(11):1933-1941.
71. Renne T, Dedio J, David G, Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem. 2000;275(43):33688-33696.
72. Renne T, Dedio J, Meijers JC, Chung D, Muller-Esterl W. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2. J Biol Chem. 1999;274(36):25777-25784.